Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $800.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target lowered by equities researchers at JPMorgan Chase & Co. from $950.00 to $800.00 in a research report issued on Monday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 53.30% from the company's previous close.

REGN has been the subject of a number of other reports. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. UBS Group dropped their price target on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. Citigroup decreased their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Finally, BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $3.24 on Monday, reaching $521.84. The stock had a trading volume of 873,171 shares, compared to its average volume of 874,701. The stock has a market cap of $56.34 billion, a P/E ratio of 13.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,211.20. The business's 50-day moving average price is $564.76 and its 200 day moving average price is $653.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.55 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $27,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.